PMID

Data

Article Title

Organization

Exploring

University of California San Francisco

Arylsulfonamide pyrimidines as VLA-4 antagonists.

Elan Pharmaceuticals

Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.

Pfizer

Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.

Pfizer

Synthesis of cinnamic acids and related isosteres as potent and selective alpha v beta 3 receptor antagonists.

Pfizer

Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds.

Pharmaceutical Research Institute

Discovery of the first potent and selective ?

University of Strathclyde

Dual antagonists of ?5?1/?v?1 integrin for airway hyperresponsiveness.

University of California San Francisco

Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.

Pliant Therapeutics

Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.

Smithkline Beecham Pharmaceuticals

Profile of a Highly Selective Quaternized Pyrrolidine Betaine ?

Glaxosmithkline Medicines Research Centre

Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.

University of Bradford

Discovery of ( S)-3-(3-(3,5-Dimethyl-1 H-pyrazol-1-yl)phenyl)-4-(( R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic Acid, a Nonpeptidic ?

University of Strathclyde